COMPUTATIONAL ASSESSMENT OF DIFFERENT CANCER CONTROLLING DRUGS

In clinic different chemotherapeutic drugs are used for cancer treatment. Among these, adjuvant and anti-angiogenic groups of drugs are considered to be safe and less toxic, as conventional pharmacological or toxicological analyses do not report any adversity. However, several scanty reports suggest some toxicity when used for long term. Molecular docking based computational analysis showed several off-target toxicity of different clinically used drugs. Moreover, heavy metal namely, arsenic, deposition or toxicity causes cancer of several organs. Though several arsenic chelator drugs are available, but conventional pharmacological investigations do not find any organ specific (chelator) drug. In this aspect computational molecular docking based analysis may help us to choose a specific drug for removing arsenic deposit from a particular organ. Moreover molecular docking studies established the importance of blood albumin analysis for early detection of arsenic toxicity. Overall this work entails that computational molecular docking based analysis could be helpful where conventional pharmacological and/or toxicological analysis is not possible.

Autorentext

Dr. D. Majumder is an Assistant Professor of Physiology, West Bengal State University, has more than 25 years of multi-disciplinary research experience in the field of Clinical Cancer research by working in Medicine, Science and Engineering schools of different National level institutes of India and published more than 50 research publications.